Clinical trials: Palmoplantar Pustulosis
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT06295692
- Testing
- JNJ-77242113
- Where
- 12 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
- Trial name
- POPLAR (NCT03633396)
- Testing
- Imsidolimab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Vanda Pharmaceuticals
Hidradenitis Suppurativa, Palmoplantar Pustulosis
Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis.
- Trial name
- NCT03972280
- Testing
- Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
- Where
- 11 sites in Australia, Denmark and 1 more
- Volunteers
- 39 people
- Sponsor
- CSL Behring
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
- Trial name
- BeSeen (NCT07219420)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Canada and 11 more
- Volunteers
- 320 people
- Sponsor
- UCB Biopharma SRL